Pharma Deals Review, Vol 2006, No 69 (2006)

Font Size:  Small  Medium  Large

BioCryst Collaborates in Oncology with Mundipharma

Business Review Editor

Abstract


Mundipharma International has entered into an exclusive in-licensing agreement for BCX-1777 (Fodosine™, forodesine hydrochloride) for oncology indications with BioCryst Pharmaceuticals. The deal could worth up to US$190 M.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.